📊 HURA Key Takeaways
Is TuHURA Biosciences, Inc./NV (HURA) a Good Investment?
TuHURA is a pre-revenue biotech company in acute financial distress with zero sales, -$27.6M operating cash burn, and only $3.6M cash reserves (sufficient for ~6 weeks of operations). The company faces imminent liquidity crisis with current ratio of 0.78x and cannot cover short-term obligations with current assets, requiring immediate capital infusion to avoid insolvency.
TuHURA is a pre-revenue biotech with substantial operating losses and deeply negative returns (ROE/ROA), funded primarily by equity. With only $3.6M in cash, a sub-1.0 current ratio, and a -$27.6M operating cash burn, fundamentals point to near-term liquidity pressure and a high likelihood of dilution absent non-dilutive funding or partnerships.
Why Buy TuHURA Biosciences, Inc./NV Stock? HURA Key Strengths
- Minimal debt burden (Debt/Equity 0.00x, long-term debt only $265K)
- Positive stockholders' equity of $20.9M provides some asset backing
- Engagement indicated by 5 insider Form 4 filings in last 90 days
- Debt-light balance sheet (D/E ~0)
- Assets exceed liabilities; positive book equity
- Minimal capital expenditure needs
HURA Stock Risks: TuHURA Biosciences, Inc./NV Investment Risks
- Zero revenue and no clear path to profitability without successful product launch
- Critical liquidity crisis: current ratio 0.78x with $3.6M cash against $27.6M annual cash burn
- Deeply negative returns: ROE -143.6%, ROA -109.9%, suggesting severe capital inefficiency
- Unsustainable cash burn rate will necessitate dilutive financing or bankruptcy within months
- Near-term liquidity shortfall (current ratio 0.78x; low cash)
- Sustained heavy cash burn with no revenue
- High dilution and going-concern risk
Key Metrics to Watch
- Cash balance and runway (critical near-term survival metric)
- Revenue generation timeline from pipeline assets
- Capital raise announcements and dilution impact on equity
- Quarterly operating cash burn (OCF)
- Cash and equivalents / runway
TuHURA Biosciences, Inc./NV (HURA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
HURA Profit Margin, ROE & Profitability Analysis
HURA vs Healthcare Sector: How TuHURA Biosciences, Inc./NV Compares
How TuHURA Biosciences, Inc./NV compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is TuHURA Biosciences, Inc./NV Stock Overvalued? HURA Valuation Analysis 2026
Based on fundamental analysis, TuHURA Biosciences, Inc./NV has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
TuHURA Biosciences, Inc./NV Balance Sheet: HURA Debt, Cash & Liquidity
HURA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: TuHURA Biosciences, Inc./NV's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.21 indicates the company is currently unprofitable.
HURA Revenue Growth, EPS Growth & YoY Performance
HURA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$4.8M | $-0.14 |
| Q2 2025 | N/A | -$4.8M | $-0.21 |
| Q1 2025 | N/A | -$2.2M | $-0.15 |
| Q2 2013 | N/A | -$3.3K | N/A |
| Q2 2012 | N/A | -$10.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
TuHURA Biosciences, Inc./NV Dividends, Buybacks & Capital Allocation
HURA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for TuHURA Biosciences, Inc./NV (CIK: 0001498382)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HURA
What is the AI rating for HURA?
TuHURA Biosciences, Inc./NV (HURA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HURA's key strengths?
Claude: Minimal debt burden (Debt/Equity 0.00x, long-term debt only $265K). Positive stockholders' equity of $20.9M provides some asset backing. ChatGPT: Debt-light balance sheet (D/E ~0). Assets exceed liabilities; positive book equity.
What are the risks of investing in HURA?
Claude: Zero revenue and no clear path to profitability without successful product launch. Critical liquidity crisis: current ratio 0.78x with $3.6M cash against $27.6M annual cash burn. ChatGPT: Near-term liquidity shortfall (current ratio 0.78x; low cash). Sustained heavy cash burn with no revenue.
What is HURA's revenue and growth?
TuHURA Biosciences, Inc./NV reported revenue of $0.0.
Does HURA pay dividends?
TuHURA Biosciences, Inc./NV does not currently pay dividends.
Where can I find HURA SEC filings?
Official SEC filings for TuHURA Biosciences, Inc./NV (CIK: 0001498382) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HURA's EPS?
TuHURA Biosciences, Inc./NV has a diluted EPS of $-0.63.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HURA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, TuHURA Biosciences, Inc./NV has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HURA stock overvalued or undervalued?
Valuation metrics for HURA: ROE of -143.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HURA stock in 2026?
Our dual AI analysis gives TuHURA Biosciences, Inc./NV a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HURA's free cash flow?
TuHURA Biosciences, Inc./NV's operating cash flow is $-27.6M, with capital expenditures of $76.1K.
How does HURA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -143.6% (avg: 15%), current ratio 0.78 (avg: 2).